116 results about "Carcinomatoses" patented technology

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field energy to target tissue areas in a specific dose so as to obtain a superior outcome. The specialized PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. The specialized PEF energy provides superior outcomes to radiofrequency ablation and irreversible electroporation.

The present invention relates to a method which allows for determining if the lung nodules of a patient are benign or cancerous. Furthermore the method also allows to determine if a patient is at high risk of developing lung cancer and if it should be subject to medical intervention.

Methods, devices and systems are described that enable identification of cancerous or pre-cancerous colon tissue. The described methods and systems rely on non-imaging. randomly sampled second harmonic generation (SHG) intensity measurements that are sufficient for differentiating between tumor and normal tissue. The disclosed methods and system further provide for angle-resolved SHG measurements associated with forward and backward scattered light that eliminate the need to obtain paired normal and cancer-suspicious measurements in each patient using the described techniques.

Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

An angiotensin II receptor antagonist and the use thereof for treating cancerous pain. Specifically, the present invention relates to a compound of formula (IV) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopic label, metabolite or prodrug thereof, and the use thereof for treating cancerous pain, preferably cancerous ostalgia.

Systems and methods are provided for treating cervical and / or uterine cancers in brachytherapy with an intracavitary brachytherapy applicator. The system comprises a tandem adapted for insertion into a cervix of a patient. An ovoid assembly comprises first and second inflatable ovoids and an ovoid support mechanism. The first and second inflatable ovoids are adapted for insertion within fornices of a patient. First and second retractors are adapted to be coupled to the ovoid assembly. The first retractor is adapted to be positioned to retract the bladder of a patient during treatment. The second retractor is adapted to be positioned to retract the rectum of a patient during treatment. The tandem and the first and second inflatable ovoids are adapted to be coupled to a radioactive source to deliver an implant radiation dose suitable for cancer treatment at a cancerous cervical treatment site in a patient.

Disclosed herein are methods for profiling a cancerous tumor using a high-throughput sequencing technique.

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.

The present application is related to a panel of antibody-drug conjugates (ADCs) in which cytotoxic tubulin inhibitor monomethyl auristatin E (MMAE) is conjugated onto monoclonal antibodies targeting cadherin-17 (CDH17), a tumor-associated antigen that is overexpressed in uterine cervical adenocarcinoma, mucinous carcinoma of the ovary, and gastrointestinal cancers including pancreatic, gastric, colorectal cancers, etc. These ADCs recognise different parts of CDH17, showing high-affinity binding to CDH17-expressing cells. All these properties allow the CDH17-targeting ADCs to demonstrate cytotoxicity specifically against CDH17-expressing cancer cells. The cytotoxic effect of MMAE would be highly localized in tumors, maximising the anti-tumor effect and simultaneously reducing the adverse effects of anti-cancer drug on non- cancerous normal tissues.

A method for a method for treatment of cholangiocarcinoma (CCA) with cold atmospheric plasma and Folfirinox. The method includes treating a patient having CCA with a low dosage FOLFIRINOX regimen, for example, 6.73 nM, giving the patient the low-dosage FOLFIRINOX regimen pre-operatively, surgically removing the cancerous tumor from the patient, continuing the low-dosage FOLFIRINOX treatment regimen intra-operatively, applying cold atmospheric plasma to the surgical margins surrounding the area in the patient from which the tumor was removed, and continuing the FOLFIRINOX post-operatively.

A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.

Embodiments herein relate to a method for treating a cancerous tumor in a subject. The method may include applying one or more electric fields at or near a site of a cancerous tumor, wherein the cancerous tumor may comprise a population of cancerous cells. The applied one or more electric fields are effective to delay mitotic division and induce mitotic synchronization within a proportion of cancerous cell populations. The method may include removing the one or more electric fields to allow mitosis within the cancerous cell population. The method may include administering a chemotherapeutic agent to the subject after the one or more electric fields have been removed. Other embodiments are also included herein.

A method for treating a non-cancerous gynecological condition, the method comprising administering to a patient an effective amount of a composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in mucosal form, such as intravaginal.

The invention discloses a traditional Chinese medicine suppository for treating low-level incomplete cancerous intestinal obstruction. The traditional Chinese medicine suppository comprises the following raw materials in parts by weight: 10-30 parts of seaweed, 10-20 parts of radix aucklandiae, 5-15 parts of rheum officinale, 10-20 parts of fried semen brassicae, 10-30 parts of fried semen raphani, 10-20 parts of fried semen pharbitidis, 1-5 parts of vinegar-processed euphorbia pekinensis, 1-5 parts of vinegar-processed euphorbia kansui, 1-15 parts of snow lotus herb, 5-15 parts of rhodiola rosea, 1-3 parts of meconopsis horridula and 0.5-1.5 parts of alkali. The traditional Chinese medicine composition is scientific and reasonable in formula compatibility, can effectively improve intestinal microcirculation, relieve intestinal spasm, promote intestinal peristalsis and recover the intestinal conduction function so as to relieve intestinal obstruction symptoms, can be effectively used for treating low-level incomplete cancerous intestinal obstruction, and is convenient to use, free of trauma, small in side effect, stable and reliable in curative effect, good in effect and free of toxic and side effects. The traditional Chinese medicine composition is a great innovation of medicines for treating low-level incomplete cancerous intestinal obstruction, and has huge social and economic benefits.

The present invention relates to an antibody or fragment thereof specifically binding to meningeosis carcinoma-specific antigen, such as DDX53, KIF3C, and AKR1A1, an anti-body or fragment thereof for use in the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, a pharmaceutical composition comprising said antibody or fragment thereof, a nucleic acid encoding said antibody or fragment thereof, a vector comprising said nucleic acid, a prokaryotic or eukaryotic host cell comprising said vector, and to a method for the prophylaxis and / or treatment of cancer, preferably melanoma, further preferably melanoma with leptomeningeal spread, highly preferably melanoma with meningeosis carcinomatosa, in a living being, comprising the admin- istration of a prophylactically and / or therapeutically effective amount of said antibody or fragment thereof or said pharmaceutical composition.

Pharmaceutical compositions including one or more integrin activators capable of capable of improving the anti-cancer activity of nature t-cells, wherein the integrin activators target integrins including, but not limited to, α4β1, α4β7, α5β1, αLβ2 and / or αVβ3 improving binding to their respective ligands including, but not limited to, VCAM-1, fibronectin, MAdCAM-1, ICAM-1, ICAM-2, and / or vitronectin, wherein the compositions treat, ameliorate, and / or reduce symptoms of diseases, maladies, and cancers, and methods for making and using for preventing, treating, ameliorating, and / or reducing symptoms of cancerous tumors, cancerous solid tumors, other cancerous growth, and / or other cancerous.

Provided is a coordination compound represented by formula (I). Also provided is a pharmaceutical composition that can be used to treat cancers, including the coordination compound of formula (I) and a pharmaceutically acceptable carrier. Also provided are applications of the coordination compound in inhibiting cancer cell survival or proliferation, inhibiting cancer cell migration or invasion, and treating cancerous tumors in a subject in need.

A system for detecting a lung cancer nodule, including: a memory module operable to store computer program code and information of a group of candidate discernible objects (CDOs) within at least one image of a lung, the group including discernible objects having associated tissue-signal response patterns corresponding to cancerous nodules. The memory, computer program code, with at least one processor are configured to cause the system to: access the information of the group of CDOs; determine for each of multiple CDOs whether that CDO satisfies an isolation requirement with respect to the rest of the CDOs, based at least on geometric remoteness from the other CDOs; based on determining that a first CDO meets the isolation criteria reporting that first CDO as a suspected nodule; and based on determining that a second CDO does not meet the isolation criteria refraining from reporting that second CDO as a suspected nodule.

Disclosed herein systems, processors, or computer-readable media configured with instructions to: receive transmission and / or reflection images of a tissue of a subject, wherein the images are generated from acoustic signals derived from acoustic waveforms transmitted through the tissue; provide a set of prognostic parameters associated with a user selected region of interest; wherein the set of prognostic parameters comprises sound propagation metrics characterizing sound propagation within a tissue; wherein the set of prognostic parameters corresponds to inputs into a tissue classifier model; wherein the set of prognostic parameters comprises a plurality of subsets of related feature groupings; and determine a type of tissue of the subject based on said plurality of subsets of related feature groupings using the classifier model, wherein the type of tissue is a cancerous tumor, a fibroadenoma, a cyst, a nonspecific benign mass, and an unidentifiable mass.

The invention provides an injection capable of treating various cancerous pains and postoperative pains and a preparation method of the injection, and relates to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: filling nitrogen into water for injection at the temperature of 30-60 DEG C, sequentially adding sodium chloride, citric acid and sodium citrate according to a preparation amount, stirring to dissolve the sodium chloride, the citric acid and the sodium citrate, then adding butorphanol tartrate according to a preparation amount, and stirring until the butorphanol tartrate is completely dissolved for later use. According to the preparation method of the butorphinol tartrate injection provided by the invention, the technological parameters are accurately controlled, and the reference preparation prescription of the butorphinol tartrate injection does not need to be changed, so that the sterile guarantee level of the butorphinol tartrate injection can be improved, the increase of the impurity content can be effectively controlled, and the good stability of the butorphinol tartrate injection is ensured.

The present disclosure provides compositions and methods for distinguishing between non-cancerous, pre-cancerous, and cancerous conditions in the esophagus. In particular, the present disclosure provides compositions and methods for distinguishing non-dysplastic Barrett's esophagus (NDBE) samples from pre-cancerous (e.g., low-grade or high-grade dysplasia) and / or cancerous (e.g., esophageal adenocarcinoma) samples based on methylation status and / or DNA copy number abnormalities.

An object of the present invention is to provide a therapeutic agent for carcinomatous peritonitis. According to the present invention, there can be provided a therapeutic agent for carcinomatous peritonitis containing an antibody that recognizes the transferrin receptor.

Embodiments herein relate to a medical device system including an electric field shaping element for treating a cancerous tumor within body tissue. In an embodiment, a method for treating a cancerous tumor is provided. The method may include implanting one or more electrodes within a patient, and measuring an impedance of tissue within the patient along a vector across or near a cancerous tumor. The method may also include applying an electric field to a cancerous tumor of the patient based on the measured impedance. Other embodiments are also included herein.

The present invention provides fully human antibodies that bind to the RET receptor tyrosine kinase, compositions comprising the antibodies, and methods of use. The antibodies of the present invention are useful for treating diseases, disorders, or conditions associated with the expression, activation, or signaling of the RET receptor tyrosine kinase gene or rearranged forms thereof, including cancerous conditions and cancer-related pain, or for alleviating pain associated with other conditions that are at least partially attributable to the expression, activation, or signaling of RET. The antibodies specific for RET may be useful for retarding tumor cell growth or tumor cell proliferation and may also be useful for alleviating pain associated with the cancer and other conditions. The antibodies may also be useful for diagnosing diseases, disorders, or conditions associated with RET activation or signaling.

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

Described herein are Methods, systems, compositions, and macromolecule complexes, for detecting, analyzing, evaluating, screening for, prognosing, diagnosing, and / or monitoring, pre-cancerous and cancerous conditions with abnormal cell growth in a patient, including patients having Minimal Residual Disease (MRD).

The invention relates to a salt and a crystal form of a polycyclic anaplastic lymphoma kinase inhibitor, a preparation method of the salt and the crystal form, a pharmaceutical composition containing the salt and the crystal form, and application of the salt and the crystal form or the pharmaceutical composition. Specifically, the invention relates to a salt and a crystal form of a compound 5-chloro-N4-(2-(isopropyl sulfonyl) phenyl)-N2-(7-methyl-8-(piperidine-4-yl)-2, 3-dihydrobenzo [b] [1, 4] dioxin-5-yl) pyrimidine-2, 4-diamine used as an anaplastic lymphoma kinase inhibitor, a preparation method of the salt and the crystal form, a pharmaceutical composition containing the salt and the crystal form, and a preparation method of the pharmaceutical composition. The invention also discloses application of the salt and the crystal form or the pharmaceutical composition in drugs for preventing and / or treating anaplastic lymphoma kinase mediated cancers or non-cancerous related diseases.